Core Insights - Stereotaxis is participating in the Piper Sandler 37th Annual Healthcare Conference, with CEO David Fischel scheduled for a discussion and one-on-one meetings on December 3, 2025 [1][2] Company Overview - Stereotaxis is a leader in surgical robotics for minimally invasive endovascular interventions, focusing on the development of robotic systems and solutions that enhance patient care and operational efficiency [2] - The company's technology has been utilized to treat over 150,000 patients globally, indicating a significant market presence [2]

Core Viewpoint - Stereotaxis, Inc. has announced a registered direct offering to sell approximately $12.5 million of its common stock at a price of $2.00 per share, aimed at accelerating product commercialization and supporting research and development efforts [1][2]. Group 1: Offering Details - The gross proceeds from the offering are expected to be around $12.5 million, with an initial closing of approximately $8.5 million expected on or about July 18, 2025, and a second closing of $4.0 million scheduled for on or before November 25, 2025 [3]. - Lake Street Capital Markets LLC is acting as the exclusive placement agent for the offering [3]. Group 2: Use of Proceeds - Proceeds from the offering will be utilized to accelerate product commercialization, support research and development, and for other corporate purposes [2]. Group 3: Company Overview - Stereotaxis is a leader in surgical robotics for minimally invasive endovascular intervention, with a mission to develop robotic systems and solutions that enhance patient care and operational efficiency [6]. - The company's technology has been used to treat over 150,000 patients globally, indicating a significant market presence [6].